I-Mab Stock Price, News & Analysis

I-Mab (Nasdaq: IMAB) and MorphoSys (Nasdaq: MOR) have initiated a phase 1 dose escalation study for TJ210/MOR210 in the U.S., focusing on patients with relapsed or refractory advanced solid tumors. This monoclonal antibody targets the C5a receptor, aiming to disrupt tumor-promoting myeloid cells. Preclinical studies indicate safety and anti-tumor activity. The trial will inform the safety and tolerability of TJ210/MOR210, with future combination studies planned. MorphoSys will receive a $1.5 million milestone payment from I-Mab as part of their collaboration agreement.

I-Mab (Nasdaq: IMAB), a clinical stage biopharmaceutical company, announced its participation in several upcoming conferences in January 2021. Key events include the H.C. Wainwright BioConnect 2021 Conference on January 11, and the Citi and UBS Greater China Healthcare Corporate Days on January 14-15 and January 18-22, respectively. Notable management participants include founder Dr. Jingwu Zang and CEO Dr. Joan Huaqiong Shen. I-Mab focuses on developing novel biologics for immuno-oncology and autoimmune diseases, striving to transition into a fully integrated global biopharmaceutical entity.

I-Mab (Nasdaq: IMAB) announced on December 14, 2020, that its American Depositary Shares (ADS) will be included in the NASDAQ Biotechnology Index, effective December 21, 2020. This inclusion marks a significant milestone, highlighting the company's progress since its IPO in January 2020. I-Mab aims to enhance its capital market profile and provide value to shareholders, with a pipeline focused on immuno-oncology and autoimmune diseases. The NBI tracks biotechnology and pharmaceutical securities, allowing investors to follow market trends.

I-Mab (Nasdaq: IMAB) announced the advancement of its clinical development for the anti-CD47 monoclonal antibody, lemzoparlimab, in the US and China, achieving key milestones. The US combination trial will evaluate lemzoparlimab with Rituxan® and Keytruda® in non-Hodgkin lymphoma and advanced tumors, with results expected next year. In China, a phase 1/2a trial and a new IND application for a combination trial with azacitidine in AML/MDS have been accepted. I-Mab's partnership with AbbVie will support global development, positioning the company for significant advancements in cancer therapy.

I-Mab (Nasdaq: IMAB) filed a registration statement on Form F-1 with the SEC for 25,123,751 ordinary shares, equivalent to 10,923,370 American depositary shares. These shares are beneficially owned by PIPE Investors under subscription agreements dated September 3, 2020. The preliminary prospectus is available on the SEC's website. This announcement does not constitute an offer to sell securities prior to registration.

I-Mab focuses on developing novel biologics in immuno-oncology and autoimmune diseases, aiming to transition into a fully integrated global biopharmaceutical company.

I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company, has enhanced its Scientific Advisory Board with the appointments of Dr. Chen Dong and Dr. Jun Ma. Both experts bring extensive knowledge in immunology and hematology, respectively. Dr. Dong, a leading immunologist, is recognized for his contributions to T cell biology, while Dr. Ma specializes in treatments for leukemia and lymphoma. Their expertise aims to advance I-Mab's mission of developing transformational medicines for patients worldwide.

I-Mab (Nasdaq: IMAB) announces an investor call on November 13, 2020, at 8:20 a.m. ET, to discuss preliminary results from a Phase 1 clinical trial evaluating lemzoparlimab for relapsed or refractory solid tumors. This call aims to provide detailed analysis of clinical efficacy signals from the trial, recently presented at the 2020 Society for Immunotherapy of Cancer Annual Meeting. The Company is advancing further studies of lemzoparlimab in combination with other treatments like Keytruda and Rituxan.

I-Mab (Nasdaq: IMAB) announced new preclinical data for its C5aR antibody project, TJ210/MOR210, at the SITC Annual Meeting. The data will be presented on November 12, 2020. TJ210/MOR210, developed in collaboration with MorphoSys, is an anti-C5aR monoclonal antibody designed to inhibit tumor-promoting cells. Key findings show high affinity binding to C5aR1, significant tumor growth inhibition in combination with anti-PD-1 therapy, and a favorable safety profile in toxicity studies. The FDA recently approved an IND application to initiate a phase 1 trial for advanced solid tumors.

I-Mab (Nasdaq: IMAB) announced initial results from its Phase 1 clinical trial (NCT03934814) of lemzoparlimab for treating relapsed or refractory solid tumors and lymphoma. Presented at the 2020 SITC Annual Meeting, lemzoparlimab showed strong anti-tumor activity with no dose-limiting toxicity or signs of hemolytic anemia at doses up to 30 mg/kg. Of the 20 patients, one achieved a confirmed Partial Response. Ongoing recruitment for combination therapies with pembrolizumab and rituximab is in progress, reflecting I-Mab's commitment to advancing this innovative treatment.